Technical Analysis for RAC - Race Oncology Ltd  

Grade Last Price % Change Price Change
A 1.590 -1.24% -0.020
RAC closed down 2.42 percent on Wednesday, May 15, 2024, on 1.33 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength -1.24%
Wide Bands Range Expansion -1.24%
Above Upper BB Strength -1.24%
Gapped Up Strength -1.24%
Overbought Stochastic Strength -1.24%
Upper Bollinger Band Touch Strength -1.24%
Shooting Star Candlestick Bearish -3.64%
Pocket Pivot Bullish Swing Setup -3.64%
Doji - Bearish? Reversal -3.64%
Wide Bands Range Expansion -3.64%

   Recent Intraday Alerts

Alert Time
Down 1% 35 minutes ago
Fell Below Upper Bollinger Band about 1 hour ago
Down 1 ATR about 23 hours ago
Down 5% about 23 hours ago
Down 3% about 24 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Race Oncology Ltd   Description

Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Cancer Drugs Clinical Medicine Cancers Therapy Oncology Chemotherapy Isan Leukemia

Is RAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.81
52 Week Low 0.64
Average Volume 174,358
200-Day Moving Average 1.000
50-Day Moving Average 1.356
20-Day Moving Average 1.335
10-Day Moving Average 1.362
Average True Range 0.096
RSI (14) 68.45
ADX 28.82
+DI 44.538
-DI 18.728
Chandelier Exit (Long, 3 ATRs) 1.457
Chandelier Exit (Short, 3 ATRs) 1.428
Upper Bollinger Bands 1.593
Lower Bollinger Band 1.077
Percent B (%b) 1.03
BandWidth 38.642
MACD Line 0.045
MACD Signal Line 0.005
MACD Histogram 0.0399
Fundamentals Value
Market Cap 206.34 Million
Num Shares 128 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -35.00
Price-to-Sales 0.00
Price-to-Book 48.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.865
Resistance 3 (R3) 1.870 1.790 1.823
Resistance 2 (R2) 1.790 1.725 1.788 1.808
Resistance 1 (R1) 1.700 1.685 1.660 1.695 1.794
Pivot Point 1.620 1.620 1.600 1.618 1.620
Support 1 (S1) 1.530 1.555 1.490 1.525 1.426
Support 2 (S2) 1.450 1.515 1.448 1.412
Support 3 (S3) 1.360 1.450 1.398
Support 4 (S4) 1.355